FDA Accepts Odronextamab Lymphoma Drug Resubmission
Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission
Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy. Write to Colin Kellaher at [email protected]
Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
Regeneron Pharmaceuticals is taking another shot at US Food and Drug Administration (FDA) accelerated approval for odronextamab in relapsed/refractory follicular lymphoma (r/r FL), with the agency ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the ...
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
Regeneron Pharmaceuticals, Inc. (REGN) Wednesday said that the U.S. Food and Drug Administration (FDA) has accepted resubmission of the Biologics License Application (BLA) for odronextamab to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback